# EWTX catalysts: Edgewise Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ewtx/catalysts

> Edgewise Therapeutics, Inc. (EWTX) has 8 upcoming catalysts. The next is the sevasemten primary completion, January 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Edgewise Therapeutics, Inc. |
| Ticker | EWTX (Nasdaq) |
| SEC CIK | 1710072 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ewtx |

## Cash runway

Cash $68.7M as of 2026-09-30; quarterly burn $78.3M; about 2.6 months of runway at that rate (XBRL company facts, accession 0001104659-26-122653).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2022 | [Sevasemten trial start](https://sec-api.dev/pdufa/sevasemten) | EWTX | Becker aged 12 years and above | completed | "In July 2022, we initiated our CANYON Phase 2 clinical trial of sevasemten, assessing the effect of sevasemten over a 12-month period on safety, PK, biomarkers of muscle damage (e.g., CK, troponins, myoglobin), and functional measures in individuals with Becker aged 12 years and above." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1710072/000155837025002006/ewtx-20241231x10k.htm)) |
| Nov 2022 | [Sevasemten trial start](https://sec-api.dev/pdufa/sevasemten) | EWTX |  | completed | "In November 2022, we initiated a Phase 2 Exercise Challenge Study (DUNE), to investigate the effect of sevasemten on muscle injury biomarkers following exercise, studied at a single site in Denmark." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1710072/000155837025002006/ewtx-20241231x10k.htm)) |
| Apr 2024 | [Edgewise Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed, positive | "In April 2024, we announced positive two-year topline results from the ARCH trial." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925031266/tm2510462d2_424b5.htm)) |
| April 15, 2024 | [Sevasemten topline data readout](https://sec-api.dev/pdufa/sevasemten) | EWTX | Becker | completed, positive | "In sevasemten, on April 15, 2024, we announced positive two-year topline results from the ARCH open label trial of sevasemten in adults with Becker, on December 16, 2024, we announced positive topline data from the Phase 2 CANYON trial of sevasemten in individuals with Becker, on June 26, 2025, we announced encouraging topline data from our Phase 2 Duchenne trials, LYNX and FOX, and positive data from MESA, an open label extension trial that is providing continued access to sevasemten to participants with Becker who were previously enrolled in ARCH, or completed CANYON, including the GRAND CANYON pivotal cohort, or DUNE, and on March 10, 2026, we announced additional positive data from MESA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1710072/000110465926056713/ewtx-20260331x10q.htm)) |
| September 19, 2024 | [EDG-7500 topline data readout](https://sec-api.dev/pdufa/edg-7500) | EWTX | oHCM | completed, positive | "In EDG-7500, on September 19, 2024, we announced positive topline data from the Phase 1 trial of EDG-7500 in healthy subjects and the Part A single-dose arm of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM, on April 2, 2025, we announced positive topline results from Part B and Part C of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM, and on June 16, 2026, we announced positive topline results from Part D of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1710072/000110465926122653/ewtx-20260930x10q.htm)) |
| Oct 2024 | [Translarna™ (ataluren) NDA/BLA submission](https://sec-api.dev/pdufa/ataluren) | EWTX |  | completed | "It remains unclear if the data will lead to FDA approval of Translarna, for which the company resubmitted the NDA in October 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1710072/000110465926020112/ewtx-20251231x10k.htm)) |
| Dec 2024 | [EDG-7500 topline data readout](https://sec-api.dev/pdufa/edg-7500) | EWTX |  | completed, positive | "In December 2024, the Company announced positive topline results from CANYON, the largest interventional Becker trial that evaluated" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/tm257448d1_ex99-1.htm)) |
| December 16, 2024 | [Sevasemten topline data readout](https://sec-api.dev/pdufa/sevasemten) | EWTX | Becker muscular dystrophy | completed, positive | "On December 16, 2024, the Company announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710072/000110465924129001/tm2431151d1_8k.htm)) |
| March 3, 2025 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/tm257448d1_ex99-1.htm)) |
| Q2 2025 | [Ninerafaxstat trial start](https://sec-api.dev/pdufa/ninerafaxstat) | EWTX |  | scheduled | "Imbria also announced plans to initiate a Phase 2b nHCM trial of ninerafaxstat in the second quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1710072/000155837025006857/ewtx-20250331x10q.htm)) |
| April 2, 2025 | [EDG-7500 topline data readout](https://sec-api.dev/pdufa/edg-7500) | EWTX |  | completed, positive | "On April 2, 2025, the Company announced positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive HCM." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/tm2510984d2_8k.htm)) |
| May 8, 2025 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "Boulder, Colo., (May 8, 2025) - Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2025 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925045896/tm2513845d1_ex99-1.htm)) |
| 2H 2025 | [EDG-7500 interim data readout](https://sec-api.dev/pdufa/edg-7500) | EWTX |  | scheduled | "The initial data read-out from Part D is expected in the second half of 2025, with Phase 3 initiation planned for the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/tm2510984d2_ex99-1.htm)) |
| Q3 2025 | [Edg-15400 25 mg trial start](https://sec-api.dev/pdufa/edg-15400) | EWTX | heart failure | scheduled | "During the third quarter of 2025, the Company expects to begin dosing in a first-in-human Phase 1 trial of EDG-15400, a novel drug candidate intended for the treatment of heart failure." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925074987/tm2522645d1_ex99-1.htm)) |
| August 7, 2025 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the second quarter of 2025 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925074987/tm2522645d1_ex99-1.htm)) |
| September 26, 2025 | [Edgewise Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | scheduled | "In December 2024, the FDA accepted the aficamtin New Drug Application (NDA) with a Prescription Drug User Fee Act (PDUFA) target action date set for September 26, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1710072/000155837025002006/ewtx-20241231x10k.htm)) |
| November 6, 2025 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2025 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925107419/tm2529979d1_ex99-1.htm)) |
| 1H 2026 | [Edg-15400 25 mg topline data readout](https://sec-api.dev/pdufa/edg-15400) | EWTX | heart failure with preserved ejection fraction | scheduled | "The Company expects top-line results from this study in the first half of 2026 and to initiate a Phase 2 trial in participants with heart failure with preserved ejection fraction (HFpEF) in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/tm266859d1_ex99-1.htm)) |
| February 26, 2026 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/tm266859d1_ex99-1.htm)) |
| May 7, 2026 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "(Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926056783/tm2613489d1_ex99-1.htm)) |
| Jun 2026 | [EDG-7500 topline data readout](https://sec-api.dev/pdufa/edg-7500) | EWTX |  | completed, positive | "In June 2026, we announced positive topline data for our multipart Phase 2 trial with EDG-7500 for people with HCM (CIRRUS-HCM) and are planning to initiate a Phase 3 trial for EDG-7500 in the fourth quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1710072/000110465926122653/ewtx-20260930x10q.htm)) |
| 2H 2026 | [Edg-15400 25 mg trial start](https://sec-api.dev/pdufa/edg-15400) | EWTX | heart failure with preserved ejection fraction | scheduled | "EDG-15400, our second cardiovascular product candidate, is currently in a Phase 1 trial in healthy adults, with a future disease target of heart failure with preserved ejection fraction, and we expect to initiate a Phase 2 trial in the second half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1710072/000110465926091670/ewtx-20260630x10q.htm)) |
| Aug 2026 | [EDG-7500 topline data readout](https://sec-api.dev/pdufa/edg-7500) | EWTX |  | completed, positive | "In August 2026, the Company shared positive top-line results from the 12-week Phase 2 Part D CIRRUS-HCM open label trial of EDG-7500 in obstructive and nonobstructive HCM in a late-breaking science presentation at the European Society of Cardiology Congress, which can be found here." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926122654/tm2628556d1_ex99-1.htm)) |
| August 6, 2026 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "(Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926091671/tm2621653d1_ex99-1.htm)) |
| September 7, 2026 | [Sevasemten primary completion](https://sec-api.dev/pdufa/sevasemten) | EWTX | Becker Muscular Dystrophy | completed | "NCT05291091 (Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-07 (ACTUAL); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05291091)) |
| Q4 2026 | [EDG-7500 trial start](https://sec-api.dev/pdufa/edg-7500) | EWTX |  | scheduled | "CIRRUS-HCM Phase 2 trial of EDG-7500, which included safety, echocardiographic, biomarker, and patient-reported outcome assessments across both oHCM and nHCM, the Company is expecting to initiate a Phase 3 trial in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926082902/tm2620181d1_ex99-1.htm)) |
| Q4 2026 | [Sevasemten topline data readout](https://sec-api.dev/pdufa/sevasemten) | EWTX | Becker Muscular Dystrophy | scheduled | "The Company expects to report top-line data in the fourth quarter of 2026 and is continuing preparations for a potential NDA submission to the U.S. Food and Drug Administration (FDA) for sevasemten in Becker, planned for the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/tm266859d1_ex99-1.htm)) |
| November 4, 2026 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "— Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today reported financial results for the third quarter of 2026 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465926122654/tm2628556d1_ex99-1.htm)) |
| January 2027 | [Sevasemten primary completion](https://sec-api.dev/pdufa/sevasemten) | EWTX | Duchenne Muscular Dystrophy | scheduled | "NCT05540860 (A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05540860)) |
| Jan to Apr 2027 | [Sevasemten topline data readout](https://sec-api.dev/pdufa/sevasemten) | EWTX | Duchenne Muscular Dystrophy | scheduled | "NCT05540860 (A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05540860)) |
| March 2027 | [Sevasemten primary completion](https://sec-api.dev/pdufa/sevasemten) | EWTX | Duchenne Muscular Dystrophy | scheduled | "NCT06100887 (Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06100887)) |
| Mar to Jun 2027 | [Sevasemten topline data readout](https://sec-api.dev/pdufa/sevasemten) | EWTX | Duchenne Muscular Dystrophy | scheduled | "NCT06100887 (Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06100887)) |
| December 2027 | [EDG-7500 primary completion](https://sec-api.dev/pdufa/edg-7500) | EWTX | Hypertrophic Cardiomyopathy | scheduled | "NCT06347159 (A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06347159)) |
| Dec 2027 to Mar 2028 | [EDG-7500 topline data readout](https://sec-api.dev/pdufa/edg-7500) | EWTX | Hypertrophic Cardiomyopathy | scheduled | "NCT06347159 (A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06347159)) |
| December 2027 | [Edg-15400 25 mg primary completion](https://sec-api.dev/pdufa/edg-15400) | EWTX | Heart Failure With Preserved Ejection Fraction | scheduled | "NCT07795814 (A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07795814)) |
| Dec 2027 to Mar 2028 | [Edg-15400 25 mg topline data readout](https://sec-api.dev/pdufa/edg-15400) | EWTX | Heart Failure With Preserved Ejection Fraction | scheduled | "NCT07795814 (A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07795814)) |

## Drugs

- [Edg-15400 25 mg](https://sec-api.dev/pdufa/edg-15400): heart failure with preserved ejection fraction, heart failure
- [EDG-7500](https://sec-api.dev/pdufa/edg-7500): ohcm, obstructive hcm demonstrated robust reductions in left ventricular outflow tract gradient, ohcm or nhcm, obstructive or nonobstructive hcm, Hypertrophic Cardiomyopathy
- [Ninerafaxstat](https://sec-api.dev/pdufa/ninerafaxstat): 
- [Sevasemten](https://sec-api.dev/pdufa/sevasemten): becker, becker muscular dystrophy, becker aged 12 years and above, Duchenne Muscular Dystrophy

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ewtx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "EWTX catalysts: Edgewise Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ewtx/catalysts

```bibtex
@misc{secapidev_companies_ewtx_catalysts_20261116,
  title        = {EWTX catalysts: Edgewise Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ewtx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ewtx_catalysts_20261116","title":"EWTX catalysts: Edgewise Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ewtx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
